Sanofi India (500674) investor relations material

Executive summary

• Achieved strong double-digit growth in the diabetes business, with Q2 2026 domestic sales up 14% year-over-year, driven by innovative products and public sector expansion.

• Strategic transformation completed, focusing on insulin and partnership models for legacy brands, and operational excellence drove margin expansion.

• Public sector expansion contributed 70% of diabetes business growth, supported by digital outreach in Tier 2 and Tier 3 markets.

• CSR initiatives reached over 600,000 beneficiaries, expanding healthcare access in multiple states.

• Unaudited financial results for Q2 and H1 2026 were approved, showing strong operational and profit momentum.

Financial highlights

• Q2 2026 total income rose 7% year-over-year to ₹4,439 million; sales up 6% to ₹4,162 million.

• Domestic sales rose 8% in Q2 2026, while export sales declined 2% year-over-year.

• Profit before tax and exceptional items increased 19% in Q2 2026 to INR 112 crore (₹1,123 million), with margin improvement from 24% to 27%.

• Operating expenses reduced by 5% in Q2 2026, reflecting financial discipline.

• Cash and cash equivalents increased to INR 3,590 million, up 34% year-over-year.

Outlook and guidance

• Diabetes business expected to sustain strong growth, leveraging innovation and public sector expansion.

• Partnership business (CV, CNS, OADs) expected to gradually recover, with industry-level growth anticipated by 2027.

• Continued focus on AI-enabled initiatives and customer-centric approaches to drive growth.

• Dividend payout expected to be at least in line with previous years, subject to board approval.